Omalizumab as a Long-Term Treatment for Patients with Severe Asthma. Is it Safe? Aseven-Years Study | ||||
| The Medical Journal of Cairo University | ||||
| Volume 93, Issue 03, March 2025, Page 323-330 PDF (123.63 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2025.423356 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| WAGDY ABDELFATAH, M.D.1; TAGHREED G. MOUSA, M.Sc.2; SHAKER A. AL-SHRAIF, MBBS3; WAEL GABR, M.D.4 and MOHAMED KAMAL, M.D.5 | ||||
| The Department of Chest Diseases (Internal Medicine)1, Faculty of Medicine, Suez Canal University, Clinical Pathology Department2, Ministry of Health, Ismailia, Saudi Board Certificate in Internal Medicine, Chest Diseases Department3, King Fahd Hospital, Madina, KSA, Neurology Department4 and Rheumatology Department5, Faculty of Medicine, Taibah University, KSA | ||||
| Abstract | ||||
| Background: Anti-IgE (Omalizumab) is one of the targeted therapies for severe bronchial asthma. Its real-life safety is still under scrutiny. Aim of Study: Was to evaluate the persistent efficacy and safety of Omalizumab as a long-term treatment of severe bron-chial asthma. Patients and Methods: This prospective cohort study eval-uated the long-term safety and efficacy of Omalizumab in 74 patients with severe bronchial asthma attending to the chest de-partment at King Fahd Hospital , Madina; KSA from June 2016 to August 2024. Results: Over a 7-10 year follow-up, Omalizumab demon-strated significant improvements in clinical outcomes. Oral steroid use decreased dramatically, tiotropium bromide use re-duced, and the frequency of acute exacerbations significantly declined. Pulmonary function tests (FEV1, FEV1/FVC, PEFR) showed substantial improvement. While mild side effects like injection site reactions, headache, and nausea were observed primarily in the first year, no serious adverse events such as cancer, anaphylaxis, or myocardial infarction were reported. Conclusion: These findings suggest that long-term Omali-zumab treatment in severe asthma is efficacious and well-toler-ated, with minimal side effects. | ||||
| Keywords | ||||
| Severe asthma; Omalizumab; Anti-IgE; Safety; Long-term treatment and side effects | ||||
|
Statistics Article View: 120 PDF Download: 70 |
||||
